CRBU

Caribou Biosciences, Inc. [CRBU] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CRBU Stock Summary

Top 10 Correlated ETFs

CRBU


Top 10 Correlated Stocks

CRBU


In the News

01:01 28 Mar 2024 CRBU

All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy

Caribou Biosciences, Inc. (CRBU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

12:37 28 Mar 2024 CRBU

Why Caribou Biosciences Stock Is Crashing Today

Caribou Biosciences announced that it has paused the development of experimental cell therapy CB-020. The company still has three programs in clinical testing.

04:05 28 Mar 2024 CRBU

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc.  (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's participation in the following investor conferences:

08:45 28 Mar 2024 CRBU

3 Biotech Stocks You Can Buy and Hold for the Next Decade

Catalyst buys appealing medicines or pharmaceutical assets and gets them out the door. Recursion uses AI and vast biomedical data to discover and exploit leads for new drugs.

05:20 28 Mar 2024 CRBU

3 Gene-Editing Stocks With the Potential to Mint Millionaires

Gene editing stocks have received a lot of attention throughout 2023. The intense focus on gene editing therapies and CRISPR technology is likely only to increase moving forward: The U.S. Food and Drug Administration (FDA) just approved the world's first medicine employing CRISPR technology.

01:32 28 Mar 2024 CRBU

Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?

Caribou Biosciences, Inc. (CRBU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

05:15 28 Mar 2024 CRBU

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy

Using gene therapy, companies can change patients' DNA. One type of gene therapy, called CRISPR, largely mimics a method used by bacteria to fend off viruses.

11:42 28 Mar 2024 CRBU

Caribou Biosciences: Upcoming CB-010 Data Could Send The Bears Packing

In July, Caribou Biosciences reported positive data from the Antler study of its CAR-T therapy, CB-010, and a $25M investment from PFE. Data from the dose expansion portion of the Antler study are expected in H1'24, but given previous conservative guidance for timelines from CRBU, might come in Q1'24. The Company has $396.7M in cash, which it expects to fund operations into Q4'25.

05:40 28 Mar 2024 CRBU

A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip

Caribou Biosciences stock could rocket up more than 400%, according to the consensus price target from Wall Street analysts. Caribou's lead candidate is an off-the-shelf cellular cancer therapy for lymphoma patients.

08:45 28 Mar 2024 CRBU

1 Gene Editing Stock to Buy Now, and 1 to Sell

Caribou Biosciences has plenty of money for the next year or so, and great data. Editas Medicine is far behind the competition with its lead programs.

CRBU Financial details

Company Rating
Sell
Market Cap
472.34M
Income
-99.01M
Revenue
34.48M
Book val./share
4.17
Cash/share
3.72
Dividend
-
Dividend %
-
Employees
158
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-5.26
Forward P/E
-2.5
PEG
3.59
P/S
14.67
P/B
1.21
P/C
1.38
P/FCF
-4.68
Quick Ratio
13.98
Current Ratio
14.27
Debt / Equity
0.07
LT Debt / Equity
0.07
-
-
EPS (TTM)
-1.4
EPS next Y
-2.05
EPS next Q
-0.4
EPS this Y
-15.85%
EPS next Y
46.19%
EPS next 5Y
-65%
EPS last 5Y
10.18%
Revenue last 5Y
42.89%
Revenue Q/Q
-84.96%
EPS Q/Q
225%
-
-
-
-
SMA20
-28.57%
SMA50
-
SMA100
25%
Inst Own
82.15%
Inst Trans
1.15%
ROA
-20%
ROE
-29%
ROC
-0.25%
Gross Margin
100%
Oper. Margin
-315%
Profit Margin
-264%
Payout
-
Shs Outstand
90.31M
Shs Float
79.39M
-
-
-
-
Target Price
-
52W Range
3.44-8.59
52W High
-36%
52W Low
+70.67%
RSI
37
Rel Volume
0.58
Avg Volume
1.67M
Volume
967.1K
Perf Week
-5.01%
Perf Month
-24.71%
Perf Quarter
11.55%
Perf Half Y
3.23%
-
-
-
-
Beta
2.589
-
-
Volatility
0.13%, 1.09%
Prev Close
0%
Price
5.12
Change
-0.39%

CRBU Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.210.450.30.230.47
Net income per share
-0.85-1.24-2.11-1.64-1.38
Operating cash flow per share
-1.16-1.2-1.03-1.5-1.26
Free cash flow per share
-1.19-1.25-1.13-1.61-1.42
Cash per share
1.790.5811.874.074.46
Book value per share
0.27-0.8512.254.954.99
Tangible book value per share
0.27-0.8512.254.954.99
Share holders equity per share
0.27-0.8512.254.954.99
Interest debt per share
1.550.060.460.320.37
Market cap
451.37M451.37M477.8M381.83M422.92M
Enterprise value
410.83M436.99M237.64M351.24M399.24M
P/E ratio
-19.26-13.16-7.14-3.84-4.14
Price to sales ratio
77.9836.5249.7827.5712.27
POCF ratio
-14.1-13.59-14.69-4.2-4.53
PFCF ratio
-13.72-13.07-13.41-3.9-4.03
P/B Ratio
60.48-19.261.231.271.15
PTB ratio
60.48-19.261.231.271.15
EV to sales
70.9835.3524.7625.3611.58
Enterprise value over EBITDA
-12.64-12.68-3.49-3.31-3.55
EV to operating cash flow
-12.84-13.16-7.31-3.86-4.28
EV to free cash flow
-12.49-12.66-6.67-3.58-3.81
Earnings yield
-0.05-0.08-0.14-0.26-0.24
Free cash flow yield
-0.07-0.08-0.07-0.26-0.25
Debt to equity
5.73-0.070.040.090.07
Debt to assets
0.690.040.030.070.06
Net debt to EBITDA
1.250.423.520.290.21
Current ratio
5.661.9615.159.2511.97
Interest coverage
-8.58K-1.81K-8.37K12.460
Income quality
1.370.970.490.910.91
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
2.841.142.532.741.12
Research and developement to revenue
4.082.785.445.943.25
Intangibles to total assets
0-0.07-0.01-0.030
Capex to operating cash flow
0.030.040.10.080.12
Capex to revenue
-0.15-0.11-0.33-0.51-0.34
Capex to depreciation
-1.18-1.46-3.17-4.35-3.29
Stock based compensation to revenue
0.210.080.360.850.4
Graham number
2.274.8624.1313.4912.46
ROIC
-0.521.57-0.17-0.3-0.28
Return on tangible assets
-0.38-0.89-0.15-0.26-0.23
Graham Net
-0.02-1.399.852.423.51
Working capital
46.93M11.92M365.36M232.12M310.54M
Tangible asset value
7.46M-20.95M390.67M311.37M368.4M
Net current asset value
2.54M-35.18M336.66M187.35M266.27M
Invested capital
5.73-0.070.040.090.07
Average receivables
04.57M6.64M6.39M4.26M
Average payables
02.57M3.3M2.57M2.13M
Average inventory
02.81M-14.34M-46.84M-31.29M
Days sales outstanding
251.11152.37308.95122.9140.85
Days payables outstanding
39.1827.581.48K114.88323.06
Days of inventory on hand
49.1425.8-11.54K-6.27K0
Receivables turnover
1.452.41.182.978.93
Payables turnover
9.3213.240.253.181.13
Inventory turnover
7.4314.15-0.03-0.060
ROE
-3.141.46-0.17-0.33-0.28
Capex per share
-0.03-0.05-0.1-0.12-0.16

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.060.060.060.280.04
Net income per share
-0.44-0.41-0.48-0.12-0.39
Operating cash flow per share
-0.41-0.46-0.25-0.34-0.24
Free cash flow per share
-0.44-0.49-0.29-0.4-0.27
Cash per share
4.063.744.224.043.72
Book value per share
4.934.554.394.754.17
Tangible book value per share
4.934.554.394.754.17
Share holders equity per share
4.934.554.394.754.17
Interest debt per share
0.390.40.440.330.31
Market cap
383.09M324.9M261.03M400.49M506.72M
Enterprise value
352.5M299.58M222.07M323.88M483.04M
P/E ratio
-3.55-3.25-2.21-10.01-3.67
Price to sales ratio
103.7692.7869.5116.93142.42
POCF ratio
-15.3-11.63-17.19-13.91-23.7
PFCF ratio
-14.14-10.84-14.72-11.94-21.42
P/B Ratio
1.271.170.971.011.38
PTB ratio
1.271.170.971.011.38
EV to sales
95.4885.5559.1413.69135.76
Enterprise value over EBITDA
-11.55-9.82-6.75-22.13-13.62
EV to operating cash flow
-14.08-10.72-14.62-11.25-22.59
EV to free cash flow
-13.01-10-12.52-9.66-20.42
Earnings yield
-0.07-0.08-0.11-0.02-0.07
Free cash flow yield
-0.07-0.09-0.07-0.08-0.05
Debt to equity
0.090.10.10.070.07
Debt to assets
0.070.080.080.060.06
Net debt to EBITDA
10.831.185.230.67
Current ratio
9.258.847.8114.2711.97
Interest coverage
7.4510.13000
Income quality
0.9310.512.880.62
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
2.312.542.70.412.73
Research and developement to revenue
6.977.347.061.218.79
Intangibles to total assets
-0.030000
Capex to operating cash flow
0.080.070.170.170.11
Capex to revenue
-0.56-0.58-0.68-0.2-0.64
Capex to depreciation
-4.07-3.45-4.14-3.01-1.15
Stock based compensation to revenue
0.840.890.950.151
Graham number
7.016.466.893.576.05
ROIC
-0.09-0.08-0.1-0.03-0.09
Return on tangible assets
-0.07-0.07-0.08-0.02-0.08
Graham Net
2.412.72.723.412.93
Working capital
232.12M212.39M234.16M326.12M310.54M
Tangible asset value
311.37M278.27M269.46M398.27M368.4M
Net current asset value
187.35M170.3M188.35M291.44M266.27M
Invested capital
0.090.10.10.070.07
Average receivables
4.83M4.75M4.29M4.44M4.5M
Average payables
1.19M1.9M3.54M3.41M2.75M
Average inventory
-27.56M-28.85M-12.17M-11.88M2.73M
Days sales outstanding
113.69124.4489.6919.5497.61
Days payables outstanding
114.22216.11354.33101.58142.25
Days of inventory on hand
-6.24K397.5-2.33K233.250
Receivables turnover
0.790.7214.610.92
Payables turnover
0.790.420.250.890.63
Inventory turnover
-0.010.23-0.040.390
ROE
-0.09-0.09-0.11-0.03-0.09
Capex per share
-0.03-0.03-0.04-0.06-0.03

CRBU Frequently Asked Questions

What is Caribou Biosciences, Inc. stock symbol ?

Caribou Biosciences, Inc. is a US stock , located in Berkeley of Ca and trading under the symbol CRBU

What is Caribou Biosciences, Inc. stock quote today ?

Caribou Biosciences, Inc. stock price is $5.12 today.

Is Caribou Biosciences, Inc. stock public?

Yes, Caribou Biosciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap